Aller au contenu principal
Profil bibliographique

Cristina Cravcenco

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

6Publications signalées
99Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Malaria Research and ControlImmune responses and vaccinationsVaccine Coverage and HesitancyMosquito-borne diseases and controlBacterial Infections and Vaccines

Les publications récentes

Accès ouvert 2026 article OpenAlex

A randomized trial of viral vector and adjuvanted protein HBV therapeutic vaccine in people with chronic hepatitis B on nucleos(t)ide analogs

Wen‐Juei Jeng, Chi-Jen Chu, Apinya Leerapun, Anchalee Avihingsanon et autres

BACKGROUND: This study assessed the safety, efficacy, and immunogenicity of a therapeutic immunization strategy aimed at reaching a functional cure for chronic hepatitis B (CHB), relying on a heterologous prime-boost with viral vectors ChAd155-hIi-HBV and MVA-HBV, combined with sequential or concomitant administration …

tw, th, de, be, cn, hk, es, us (code pays fourni par la source)

0 citations Hepatology Communications
Accès ouvert 2025 article OpenAlex

Effectiveness of the RTS,S/AS01E malaria vaccine in a real-world setting over 1 year of follow-up after the three-dose primary schedule: an interim analysis of a phase 4 study in Ghana, Kenya, and Malawi

Latif Ndeketa, Valérie Haine, Muriel Debois, Kwaku Poku Asante et autres

Background RTS,S/AS01 E was first introduced within the Malaria Vaccine Implementation Programme in selected areas in Ghana, Kenya, and Malawi. A series of post-introduction observational studies were initiated in these areas to assess RTS,S/AS01 E safety and effectiveness in real-world settings. Here, …

gb, Malawi, be, Ghana, in, Kenya, ca (code pays fourni par la source)

9 citations The Lancet Global Health
Accès ouvert 2025 article OpenAlex

Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial

Lawrence Osei‐Tutu, Simon Kariuki, Cynthia Lee, Robin Fabre et autres

BACKGROUND: vaccine (RTS,S). All regimens provided substantial protection against clinical malaria in natural exposure settings, over 21 and 32 months of follow-up. Here, we present end-of-study results, after 50 months of follow-up. METHODS: This open-label, randomised controlled trial was conducted at two …

Ghana, Kenya, us, be (code pays fourni par la source)

3 citations The Lancet Global Health
Accès ouvert 2025 article OpenAlex

Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022

Kwaku Poku Asante, Marie‐Cécile Bozonnat, Miloje Savic, Seth Owusu‐Agyei et autres

BACKGROUND: implementation. Interim results from EPI-MAL-002 up to Oct 5, 2018, were reported previously. Here, we report results from the final analysis of the pre-vaccine introduction study. METHODS: vaccination schedule [ie, a simulated vaccination schedule], with additional visits after the simulated schedule …

Ghana, be, Kenya (code pays fourni par la source)

4 citations The Lancet Global Health
Accès ouvert 2025 article OpenAlex

Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study

Valérie Haine, Martina Oneko, Muriel Debois, Latif Ndeketa et autres

Background RTS,S/AS01 E has been successfully administered to over two million children since 2019 through the Malaria Vaccine Implementation Programme (MVIP). In this Article, we report the safety results of a study evaluating RTS,S/AS01 E safety and effectiveness in real-world settings. Methods …

be, Kenya, gb, Malawi, Ghana, in (code pays fourni par la source)

8 citations The Lancet Global Health
Accès ouvert 2022 article OpenAlex

Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial

Aaron M. Samuels, Daniel Ansong, Simon Kariuki, Samuel Adjei et autres

Background Controlled infection studies in malaria-naive adults suggest increased vaccine efficacy for fractional-dose versus full-dose regimens of RTS,S/AS01. We report first results of an ongoing trial assessing different fractional-dose regimens in children, in natural exposure settings. Methods This open-label, phase 2b, randomised …

us, Kenya, Ghana, be (code pays fourni par la source)

75 citations The Lancet Infectious Diseases

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.